Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis

Randomized, Double-blind Placebo-controlled Multi-center Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Psoriatic Arthritis

This study is designed as a proof of concept of AIN457 in patients with psoriatic arthritis. The study will address the evaluation of the efficacy at 6 and up to 24 weeks after two doses of AIN457 10 mg/kg administered three weeks apart.

Inclusion Criteria:

• A diagnosis of psoriatic arthritis

Exclusion Criteria:

• Patients with arthritis or ankylosing spondyitis
• Drug-induced psoriasis
• Male or female patients who plan to conceive during the time course of the study, or for 6 months after the administration of the second dose.
• Participation in any clinical trial within 4 weeks prior to initial dosing or longer.
• Previous use of immunosuppressive agents eg cyclosporine, without the necessary wash-out period
• History of severe allergy to food or drugs
• Positive TB test. Other protocol-defined inclusion/exclusion criteria may apply